2019
Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators.
Womack JA, Murphy TE, Rentsch CT, Tate JP, Bathulapalli H, Smith AC, Bates J, Jarad S, Gibert CL, Rodriguez-Barradas MC, Tien PC, Yin MT, Gill TM, Friedlaender G, Brandt CA, Justice AC. Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 305-313. PMID: 31339866, PMCID: PMC7176040, DOI: 10.1097/qai.0000000000002130.Peer-Reviewed Original ResearchConceptsIllicit substance useHazardous alcoholSerious fallsUninfected comparatorsMedication classesOpioid prescriptionsSubstance useHIV statusMuscle relaxantsRisk factorsVeterans Aging Cohort StudyAging Cohort StudyIllicit substance abuseUnconditional logistic regressionNon-ART medicationsHazardous alcohol useSubstance use/abuseCase-control designKey risk factorsUse/abuseCohort studyMedication countInjury codesDuration of observationBaseline date
2011
A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease
Vanasse GJ, Jeong JY, Tate J, Bathulapalli H, Anderson D, Steen H, Fleming M, Mattocks K, Telenti A, Fellay J, Justice AC, Berliner N. A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. Blood 2011, 118: 5401-5408. PMID: 21926355, PMCID: PMC3217345, DOI: 10.1182/blood-2011-06-362194.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyCombined antiretroviral therapyPrevalence of anemiaHIV diseaseSingle nucleotide polymorphismsModern combined antiretroviral therapyWorld Health Organization criteriaAging Cohort StudyA Single Nucleotide PolymorphismGene single nucleotide polymorphismsLeptin gene promoterHIV subjectsAntiretroviral therapyCohort studyHIV statusOrganization criteriaClinical dataIndependent cohortAnemiaHIVPatientsLeptin genePrevalenceDiseaseCandidate gene approach